Literature DB >> 264200

Dopamine in the management of shock.

W L Thompson.   

Abstract

Shock is a syndrome with serious prognostic implications--the harbinger of death. Hypoperfusion of essential organs is common, though total blood flow may be significantly greater than normal. Specific therapy is directed to the specific inciting event--infection, abscess, tamponade, &c. Symptomatic therapy keeps the patient alive until we discover the specific problem or until he recovers spontaneously. The intravascular volume must be carefully monitored and corrected, using the pulmonary wedge pressure as the principal guide, and colloid osmotic pressure must be maintained. If the patient does not respond to volume augmentation alone then inotropic drugs may be needed, and of these dopamine is a selective vasodilator which redirects blood flow to the critical organs. The outstanding challenge in shock is the maldistribution of perfusion in the microvasculature. Although this may be ameliorated by the early administration of large doses of glucocorticoids, there is little convincing that these drugs constitute more than supportive therapy. Of greatest importance is reevaluation, reevaluation, and reevaluation. The patient in shock becomes a new patient every five minutes. Drugs that formerly worked, doses previously optimal--these are no guide because the situation changes so rapidly. The principles of management are to monitor vital functions, constantly vary drugs and doses, and continually attempt to put right all the parameters measured. This strategy will be more effective when we know what parameters to measure.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 264200      PMCID: PMC1543336     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


  19 in total

1.  Role of cortisol in the restitution of blood volume after hemorrhage.

Authors:  D S Gann; J C Pirkle
Journal:  Am J Surg       Date:  1975-11       Impact factor: 2.565

2.  The automated physiologic profile.

Authors:  J D Cohn; P E Engler; L R Del Guercio
Journal:  Crit Care Med       Date:  1975 Mar-Apr       Impact factor: 7.598

3.  An ethical consideration of large-scale clinical trials in cardiovascular diseases. Report of the Committee on Ethics of the American Heart Association.

Authors: 
Journal:  Circulation       Date:  1975-09       Impact factor: 29.690

4.  Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema.

Authors:  A C GUYTON; A W LINDSEY
Journal:  Circ Res       Date:  1959-07       Impact factor: 17.367

5.  Method for estimation of the perfusion defect in shock.

Authors:  W C Shoemaker; W J Launder; J Castagna; D State
Journal:  J Surg Res       Date:  1976-02       Impact factor: 2.192

6.  Analysis of factors affecting partial pressures of oxygen and carbon dioxide in gas and blood of lungs; theory.

Authors:  R L RILEY; A COURNAND
Journal:  J Appl Physiol       Date:  1951-08       Impact factor: 3.531

7.  Objective index of haemodynamics status for quantitation of severity and prognosis of shock complicating myocardial infarction.

Authors:  H Shubin; A A Afifi; W M Rand; M H Weil
Journal:  Cardiovasc Res       Date:  1968-10       Impact factor: 10.787

8.  Abnormal vascular tone, defective oxygen transport and myocardial failure in human septic shock.

Authors:  J H Siegel; M Greenspan; L R Del Guercio
Journal:  Ann Surg       Date:  1967-04       Impact factor: 12.969

9.  Rattlesnake venom shock in the rat: development of a method.

Authors:  R W Carlson; R C Schaeffer; H Whigham; S Michaels; F E Russell; M H Weil
Journal:  Am J Physiol       Date:  1975-12

10.  Application of statistical techniques for assessment of prognosis in patients with acute circulatory failure (shock).

Authors:  P Winkel; A A Afifi; L D Cady; M H Weil; H Shubin
Journal:  J Chronic Dis       Date:  1971-06
View more
  2 in total

Review 1.  Inotropic drugs in acute circulatory failure.

Authors:  P Herbert; J Tinker
Journal:  Intensive Care Med       Date:  1980       Impact factor: 17.440

2.  Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects.

Authors:  U Gundert-Remy; J Penzien; R Hildebrandt; W Mäurer; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.